Medigene AG announces closing of its first SEPA tranche

Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced the closing of its first tranche of the Standby Equity Purchase Agreement (“SEPA”) with a fund managed by Yorkville Advisors Global, LP (“Yorkville”) announced on January 24, 2024. The subscription price was set at EUR 1.70 and is equal to 95% of the aver ...